|
LINC01194
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We present the results of a phase I clinical trial of recombinant plasmid DNA and modified vaccinia Ankara (MVA), both encoding 7 melanoma tumor antigen cytotoxic T lymphocyte (CTL) epitopes.
|
15386406 |
2005 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently published or communicated clinical experiences and ongoing trials have used defined tumor antigen RNA transfection for prostate carcinoma and melanoma, liposome-encoated DNA transfection for breast or pancreatic cancer, adenoviral vector tumor antigen gene modification for melanoma and small cell lung cancer, and poxvirus-mediated expression of costimulatory molecules for colon carcinoma.
|
16457651 |
2005 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Due to its tumor-restricted expression pattern and its recognition by both cytotoxic and helper T cells it constitutes a promising tumor antigen for anticancer immunotherapy, notably of malignant melanoma.
|
15570431 |
2005 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, a unique tumor antigen can be as immunogenic as the melanoma differentiation antigens but, in contrast to the latter, may be retained in all metastatic cells possibly as result of the relevant cellular function exerted by the mutated protein.
|
15695408 |
2005 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associated with tumor regression was also loss of the melanoma common tumor antigen Melan A/ MART-1 in the multiple primary melanoma patients as compared to the single primary ones (P=0.0041).
|
16248806 |
2005 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
The properties of the TAG antigens indicate that they are excellent vaccine candidates for the treatment of melanoma and perhaps other cancers.
|
14871852 |
2004 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
|
12960359 |
2003 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
|
12359758 |
2002 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types.
|
11565834 |
2002 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously reported the presence of OX-40(+) T cells in head and neck cancer and melanoma, where they appear to be restricted to tumor compartments (primary tumor infiltrating lymphocytes [TILs] and draining lymph node cells) and therefore may represent the tumor antigen-specific CD4(+) T cells.
|
10930490 |
2000 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using several different preexisting tumor models that make use of B16F10 melanoma cells expressing a target tumor antigen (human melanoma-associated gene [MAGE]-1), we found that vaccination with bone marrow-derived DCs engineered to express MAGE-1 via adenoviral-mediated gene transfer led to a dramatic decrease in the number of metastases in a lung metastasis model, and led to prolonged survival and some long-term cures in a subcutaneous preexisting tumor model.
|
10811863 |
2000 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
The human tyrosinase-derived peptide YMDGTMSQV is presented on the surface of human histocompatibility leukocyte antigen (HLA)-A*0201(+) melanomas and has been suggested to be a tumor antigen despite the fact that tyrosinase is also expressed in melanocytes.
|
10748239 |
2000 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HOM-MEL-40 antigen which is encoded by the SSX-2 gene was originally detected as a tumor antigen recognized by autologous IgG antibodies in a melanoma patient.
|
9639388 |
1998 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MART-1/Melan-A human melanoma tumor antigen can be recognized by T lymphocytes and appears to be involved in tumor regression.
|
9218710 |
1997 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1.
|
7561675 |
1995 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.
|
7836932 |
1995 |